AU6078500A - Combination therapy for conditions leading to bone loss - Google Patents

Combination therapy for conditions leading to bone loss

Info

Publication number
AU6078500A
AU6078500A AU60785/00A AU6078500A AU6078500A AU 6078500 A AU6078500 A AU 6078500A AU 60785/00 A AU60785/00 A AU 60785/00A AU 6078500 A AU6078500 A AU 6078500A AU 6078500 A AU6078500 A AU 6078500A
Authority
AU
Australia
Prior art keywords
combination therapy
bone loss
conditions leading
leading
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60785/00A
Inventor
William J Boyle
Frank J. Calzone
Ming-Shi Chang
David Lee Lacey
Giorgio Senaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU6078500A publication Critical patent/AU6078500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
AU60785/00A 1999-07-09 2000-07-07 Combination therapy for conditions leading to bone loss Abandoned AU6078500A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35067099A 1999-07-09 1999-07-09
US09350670 1999-07-09
US45764799A 1999-12-09 1999-12-09
US09457647 1999-12-09
PCT/US2000/018667 WO2001003719A2 (en) 1999-07-09 2000-07-07 Combination therapy for conditions leading to bone loss

Publications (1)

Publication Number Publication Date
AU6078500A true AU6078500A (en) 2001-01-30

Family

ID=26996731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60785/00A Abandoned AU6078500A (en) 1999-07-09 2000-07-07 Combination therapy for conditions leading to bone loss

Country Status (2)

Country Link
AU (1) AU6078500A (en)
WO (1) WO2001003719A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
AU735355B2 (en) 1997-04-15 2001-07-05 Daiichi Sankyo Company, Limited Novel protein and method for producing the protein
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
TR199902512T2 (en) 1997-04-16 2000-06-21 Amgen Inc. Osteoprotegerin binding proteins and receptors.
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
PT2009025E (en) 1998-05-14 2011-09-19 Immunex Corp Method of inhibiting osteoclast activity
MXPA01004225A (en) 1998-10-28 2002-06-04 Snow Brand Milk Prod Co Ltd Remedies for bone metabolic errors.
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
JP4860897B2 (en) * 2001-01-29 2012-01-25 メルク セロノ ソシエテ アノニム Use of IL-18 inhibitors for the treatment and / or prevention of heart disease
US20050074434A1 (en) * 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
CN100594935C (en) 2001-05-25 2010-03-24 人体基因组科学有限公司 Antibodies that immunospecifically bind to trail receptors
JP2005510542A (en) * 2001-11-30 2005-04-21 ファイザー・プロダクツ・インク Combination of IL-1 / 18 inhibitor and TNF inhibitor for the treatment of inflammation.
PA8568001A1 (en) * 2002-03-01 2003-11-12 Sankyo Co PHARMACEUTICAL COMPOSITION
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2004052233A2 (en) 2002-12-10 2004-06-24 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
NZ554390A (en) * 2004-12-13 2010-07-30 Cephalon Australia Vic Pty Ltd Osteoprotegerin variant proteins
JP2009532369A (en) 2006-03-30 2009-09-10 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク Stimulation of nerve regeneration by secretory leukocyte protease inhibitor
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU672606B2 (en) * 1992-04-30 1996-10-10 Amgen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin

Also Published As

Publication number Publication date
WO2001003719A3 (en) 2002-02-21
WO2001003719A2 (en) 2001-01-18
WO2001003719A9 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AU6078500A (en) Combination therapy for conditions leading to bone loss
AU7842500A (en) System for orthopedic treatment
AU7109500A (en) Liquefracture handpiece
AU7373100A (en) Liquefracture handpiece
AU2492600A (en) Surgical handpiece
AU7496800A (en) Liquefracture handpiece
AU7059300A (en) Immediate provisional implant
AU4198500A (en) Suture-passing forceps
AU2111500A (en) Bone tissue regenerating composition
AU2955200A (en) Cannula
AU1217801A (en) External fixation system
AU5602500A (en) System for orthopedic treatment protocol
AU4067800A (en) Surgical bone screw
AU3091899A (en) Obligated investment system
AU6599800A (en) Endoscope
AU2001233208A1 (en) Human sulfatases
AU2495100A (en) Surgical handpiece
AU5547000A (en) Novel treatment
AU7730100A (en) Endoscope system
AU3978700A (en) Medical use
AUPQ232599A0 (en) Drug for treating fractures
AU1878201A (en) Composition for the treatment of damaged tissue
AU4556800A (en) Novel treatment
AU5394300A (en) Tissue engineering
AU3454900A (en) Compositions for reducing blood cholesterol

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase